Dogwood Therapeutics (DWTX) Operating Expenses (2020 - 2026)
Dogwood Therapeutics (DWTX) posted quarterly Operating Expenses of $5.1 million for Q1 2026, up 14.59% year-over-year from $4.4 million in Q1 2025, and up 33.37% quarter-over-quarter from $3.8 million in Q4 2025.
Dogwood Therapeutics (DWTX) Operating Expenses (2020 - 2026) Analysis & Trends
Dogwood Therapeutics (DWTX) has reported Operating Expenses for 7 consecutive years, with $5.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses rose 14.59% year-over-year to $5.1 million; the TTM figure through Mar 2026 stood at $28.6 million (up 86.5% YoY), while the FY2025 annual figure was $28.0 million, up 128.74% from the prior year.
- Operating Expenses climbed to $5.1 million in Q1 2026 per DWTX's latest filing, from $3.8 million in the prior quarter.
- Across five years, Operating Expenses topped out at $15.8 million in Q3 2025 and bottomed at $1.1 million in Q2 2024.
- Historically, Operating Expenses has averaged $3.7 million across 5 years, with a median of $2.6 million in 2022.
- Annual changes were most pronounced in 2023 — Operating Expenses tumbled 60.69% — and 2025, when it soared 587.0%.
- Dogwood Therapeutics' Operating Expenses stood at $2.1 million in 2022, then tumbled by 45.54% to $1.1 million in 2023, then jumped by 562.68% to $7.5 million in 2024, then sank by 49.53% to $3.8 million in 2025, then jumped by 33.37% to $5.1 million in 2026.
- Business Quant data shows DWTX's Operating Expenses at $5.1 million in Q1 2026, $3.8 million in Q4 2025, and $15.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 541.02 Mn |
| 10 | Dogwood Therapeutics | 80.55 Mn | 80.55 Mn | - | 14.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.08 Mn |
| Dec 31, 2025 | 3.81 Mn |
| Sep 30, 2025 | 15.81 Mn |
| Jun 30, 2025 | 3.92 Mn |
| Mar 31, 2025 | 4.43 Mn |
| Dec 31, 2024 | 7.54 Mn |
| Sep 30, 2024 | 2.30 Mn |
| Jun 30, 2024 | 1.07 Mn |
| Mar 31, 2024 | 1.31 Mn |
| Dec 31, 2023 | 1.14 Mn |
| Sep 30, 2023 | 1.27 Mn |
| Jun 30, 2023 | 1.48 Mn |
| Mar 31, 2023 | 1.56 Mn |
| Dec 31, 2022 | 2.09 Mn |
| Sep 30, 2022 | 2.59 Mn |
| Jun 30, 2022 | 3.67 Mn |
| Mar 31, 2022 | 3.96 Mn |
| Dec 31, 2021 | 4.19 Mn |
| Sep 30, 2021 | 4.11 Mn |
| Jun 30, 2021 | 4.28 Mn |